BioTime Reports Results from Independent Hextend Study

-- First Report on Hextend for Initial Fluid Resuscitation at a Level I Trauma Center --

ALAMEDA, Calif.--(BUSINESS WIRE)--Feb 5, 2010 - BioTime, Inc. (NYSE Amex:BTIM) today reported recently-released results from an independent study evaluating the use of Hextend® in hemodynamically unstable trauma patients. Hextend (6% Hetastarch in Lactated Electrolyte Injection) is BioTime's commercially-available blood plasma volume expander used to treat hypovolemia (low blood volume). The study, conducted at the University of Miami Ryder Trauma Center, reported that initial resuscitation with Hextend was associated with no obvious coagulopathy and reduced mortality compared to fluid resuscitation without Hextend.

The non-randomized observational trial was the largest involving Hextend in any group of surgical patients and was conducted by a team of physicians led by Kenneth G. Proctor, Ph.D. at the University of Miami Ryder Trauma Center, a Level 1 trauma center, from June 2008 through December 2008. The results were presented at the prestigious Southern Surgical Association 2009 Annual Meeting in December by Drs. Alan S. Livingstone, chair of Miami's Department of Surgery, and Michael P. Ogilvie, the study's first author. Dr. Proctor's team prospectively evaluated 1,714 patients, of which 805 patients received standard of care fluid resuscitation plus up to one liter of Hextend within the first two hours of arrival at the trauma center and 909 patients received standard of care fluid resuscitation without Hextend. Results of the study showed that overall mortality for the patients treated with Hextend was significantly lower at 5.2 percent compared to 8.9 percent (p=0.0035) for the patients receiving fluid resuscitation without Hextend. Additionally, similar benefits were seen in penetrating injuries (p=0.0016) and in those severely injured, as defined by Glasgow Coma Score <9 (p=0.0013) or Injury Severity Score >26 (p=0.0142). While survival was improved in those receiving Hextend, a higher proportion of these patients required ICU admission and transfusions of blood or plasma, consistent with lower mortality and a higher percentage of patients surviving to require subsequent critical care. All results were confirmed using univariate analysis.

“The U.S. Army has deployed Hextend for initial resuscitation of battlefield casualties because less Hextend is required compared to commonly used saline solution to achieve the same plasma volume expansion effect. This offers a major logistic advantage for a combat medic who has to carry all his supplies in his backpack,” said Dr. Proctor. “Our team was one of the first to evaluate the potential use of Hextend as a resuscitation fluid in the laboratory but no one had evaluated the safety and efficacy specifically in trauma patients even though there had been several other studies by other investigators in various other types of surgical patients.” Dr. Proctor cautioned that their “...study design has several limitations, but that the results are encouraging and warrant a randomized controlled clinical trial.” He also stated that it is “...extremely rewarding to provide solid evidence that our heroes in Iraq and Afghanistan are receiving state of the art fluid resuscitation on the battlefield.”

“We are gratified that Dr. Proctor and his distinguished team conducted this fully independent clinical trauma study of our first therapeutic product, Hextend,” said Michael D. West, Ph.D., Chief Executive Officer of BioTime. “The results verify our long-held belief about the clinical benefits of Hextend. Under our exclusive manufacturing and marketing licenses to Hospira, Inc., and CJ CheilJedang, Hextend has been a consistent revenue generator for our company. Our financial model anticipates revenues from sales of Hextend, stem cell research products, and research grants contributing to the funding of future stem cell-based human therapeutic products,” Dr. West concluded.

Hextend is a formulation of 6% hetastarch combined with a physiologically balanced crystalloid carrier that more closely mirrors plasma electrolyte balance than 6% hetastarch in 0.9% sodium chloride. The hetastarch component creates oncotic pressure, which would normally be provided by blood proteins, and permits retention of intravascular fluid. The crystalloid carrier provides electrolytes necessary for physiologic functions and has a composition resembling that of the principal ionic constituents of normal plasma. Hextend contains a normal physiological level of calcium. For complete Hextend prescribing information, please see the package insert.

An abstract of the study, along with the program of the Southern Surgical Association 2009 Annual Meeting, is available online at http://www.southernsurg.org/annualmeeting.html. The complete study will be published in the Journal of the American College of Surgeons in mid 2010.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. BioTime's subsidiary OncoCyte Corporation focuses on the therapeutic applications of stem cell technology in cancer. BioTime also plans to develop therapeutic products in China for the treatment of ophthalmologic, skin, musculo-skeletal system and hematologic diseases, including the targeting of genetically modified stem cells to tumors as a novel means of treating currently incurable forms of cancer through its subsidiary BioTime Asia. In addition to its stem cell products, BioTime markets blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment, and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime can be found on the web at www.biotimeinc.com.

Forward Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0

 

 

Contact: BioTime
Judith Segall, 510-521-3390 ext. 301
jsegall@biotimemail.com
or
Investors
EVC Group
Barbara Domingo, 415-896-6820
Douglas Sherk, 415-896-6820

 

Posted: February 2010

View comments

Hide
(web1)